Biotron Ltd. is a clinical stage Australian biotechnology company. It engages in developing and commercializing a novel small molecule approach that has the potential to treat a number of serious viral diseases. The company's technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. The company was founded in February 1999 and is headquartered in North Ryde, Australia.